

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 3)\*

**Larimar Therapeutics, Inc.**

(Name of Issuer)

**Common Stock, par value \$0.001 per share**

(Title of Class of Securities)

(CUSIP Number)

**03/31/2026**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Blue Owl Capital Holdings LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power  
10,739,492.00  
6 Shared Voting Power  
0.00  
7 Sole Dispositive Power  
10,739,492.00  
8 Shared Dispositive Power  
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

10,739,492.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

9.99 %

Type of Reporting Person (See Instructions)

PN

**Comment for Type of Reporting Person:** The reported securities represent: (i) 7,120,007 shares of Common Stock; (ii) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options; and (iii) 2,643,785 shares of Common Stock issuable upon conversion of Series A convertible preferred stock ("Series A Preferred Stock"). The reported percentage is calculated based on 103,882,937 shares of Common Stock outstanding as of March 17, 2026, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 19, 2026, as increased by (i) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options and (ii) 2,643,785 shares of Common Stock issuable upon conversion of Series A Preferred Stock.

## SCHEDULE 13G

Item 1.

Name of issuer:

- (a) Larimar Therapeutics, Inc.  
Address of issuer's principal executive offices:
- (b) Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004

Item 2.

Name of person filing:

- (a) This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."  
Address or principal business office or, if none, residence:
- (b) 399 Park Avenue, New York, New York 10022  
Citizenship:
- (c) See response to row 4 on the cover page.  
Title of class of securities:
- (d) Common Stock, par value \$0.001 per share
- (e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

See response to row 9 on the cover page. The reported securities include: (i) 7,120,007 shares of Common Stock; (ii) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options; and (iii) 2,643,785 shares of Common Stock issuable upon conversion of 500,000 shares of Series A Preferred Stock (which would be convertible into 5,000,000 shares of Common Stock in the absence of a conversion blocker that limits the Reporting Person's beneficial ownership to 9.99%). Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose.

(a) Percent of class:

(b) See response to row 11 on the cover page. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See response to row 5 on the cover page.

(ii) Shared power to vote or to direct the vote:

See response to row 6 on the cover page.

(iii) Sole power to dispose or to direct the disposition of:

See response to row 7 on the cover page.

(iv) Shared power to dispose or to direct the disposition of:

See response to row 8 on the cover page.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature: /s/ Karen Hager

Name/Title: Karen Hager / Chief Compliance Officer

Date: 05/13/2026